Financial News

Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Letter to Shareholders with Update on Key Corporate Milestones, Product Progress

  • Jupiter Wellness has announced that the “FDA of India” has approved its topical treatment for psoriasis and vitiligo, with a market launch to follow
  • The global vitiligo treatment market was valued at $1.2 billion in 2018 and is expected to grow at a CAGR of 5.8%, resulting in a value of approximately $2 billion by 2026
  • JW-500, a topical treatment for female sexual wellness, is currently in development with plans to file for pre-IND and Orphan Drug Designation within the next year

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property, recently issued a Letter to Shareholders to provide key corporate updates since the company’s last report on September 15, 2022 (https://ibn.fm/0jcD8). In addition to updates to its clinical trial pipeline, entering the potentially lucrative market of Female Sexual Wellness, and obtaining or adding to its intellectual property portfolio, Jupiter Wellness announced that India’s equivalent of the FDA has approved its topical treatment for psoriasis and vitiligo, with a market launch within the country. The company also provided a quick summary of recent highlights and an overview of products with current dispositions.

Of the five products currently in development, Jupiter Wellness is developing JW-500, a topical treatment for female sexual wellness. The company has signed an exclusive license with Rejoy, Inc. to develop prescription products for the treatment of nipple neuropathies and associated sexual problems in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback